Dover’s shares fell despite beating second quarter expectations and raising full-year outlook. Revenue increased 5% to $2.05 billion, with adjusted EPS at $2.44. Dover is undervalued, with record margins and growth investments in data centers and biopharma. Quarterly results show strong bookings and revenue growth potential in the second half.

Dover’s diverse segments all saw margin improvements in the second quarter. Engineered products, clean energy, imaging, pumps, and climate technologies reported growth and margin expansions. Dover’s strategic portfolio actions and investments in high-growth areas are driving future revenue growth and profitability. The company’s focus on clean energy and biopharma are key growth drivers.

Dover’s outlook for the full year has been raised, with revenue growth now expected to be between 4% to 6%. Adjusted EPS is forecasted to be $9.35 to $9.55, representing a 14% increase year over year. The company’s proactive measures have positioned it well to navigate economic uncertainties and tariffs. Dover’s strong balance sheet allows for both organic and inorganic growth opportunities.

Read more at CNBC: The market is getting Dover’s earnings all wrong. Here’s what the sellers are missing